论文部分内容阅读
观察以去甲长春碱为主的联合化疗治疗晚期恶性肿瘤的疗效和安全性。４５例晚期肿瘤患者接受以去甲长春碱（Ｖｉｎｏｒｅｌｂｉｎｅ）为主的联合化疗，其中非小细胞肺癌２４例，乳腺癌１１例，恶性淋巴瘤１０例。非小细胞肺癌的化疗方案为ＮＰ、ＮＥＰ和ＭＮＰ，乳腺癌为ＮＦ和ＮＡＦ，恶性淋巴瘤为ＣＨＮＰ和ＭＩＮＥ。４５例患者可评价疗效和毒性。白细胞减少Ⅰ～Ⅳ度发生率为８２．２％（按病例数）和６０．８％（按周期数），Ⅲ～Ⅳ度减少分别为２８．９％和１４．４％。血小板减少和血红蛋白减少少见。其它毒性反应有脱发（２８．９％），恶心、呕吐（２２．２％），而神经毒性并不常见。总有效率６２．２％（ＣＲ１０例，ＰＲ１８例）。非小细胞肺癌、乳腺癌和恶性淋巴瘤有效率分别为５０．０％，５４．５％和１００．０％。本组观察提示，去甲长春碱联合化疗治疗非小细胞肺癌，乳腺癌和恶性淋巴瘤有效，且可耐受。ＭＮＰ方案对非小细胞肺癌及ＭＩＮＥ方案对复发或难治性恶性淋巴瘤的疗效，值得进一步研究
Observed the efficacy and safety of non-vinblastine-based combination chemotherapy in the treatment of advanced malignant tumors. Forty-five patients with advanced cancer received combination chemotherapy with vinblastine, including 24 non-small cell lung cancers, 11 breast cancers, and 10 malignant lymphomas. The chemotherapy regimens for non-small cell lung cancer are NP, NEP, and MNP, NF and NAF for breast cancer, and CHNP and MINE for malignant lymphoma. Forty-five patients were evaluated for efficacy and toxicity. The incidence of leukopenia I to IV was 82.2% (by number of cases) and 60.8% (by number of cycles), and the reduction by III to IV was 28.9% and 14.4%, respectively. Thrombocytopenia and hemoglobin reduction are rare. Other toxicities were hair loss (28.9%), nausea and vomiting (22.2%), and neurotoxicity was uncommon. The total effective rate was 62.2% (10 cases for CR and 18 cases for PR). The effective rates of non-small cell lung cancer, breast cancer, and malignant lymphoma were 50.0%, 54.5%, and 100.0%, respectively. The observations in this group suggest that norepinephrine combined with chemotherapy for non-small cell lung cancer, breast cancer and lymphoma is effective, and can be tolerated. The efficacy of MNP regimen for non-small cell lung cancer and MINE regimen for relapsed or refractory lymphoma deserves further study